Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Doses 1st Patient in Phase 2 Chronic Cough Trial

Stockhouse Editorial August 5, 2020

LD Micro Announces Preliminary List of Presenters for the LD 500

Accesswire August 5, 2020

Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil

GlobeNewswire August 5, 2020

First US Clinical Trial for Possible COVID-19 Treatment About to Start

Dave Jackson July 24, 2020

Algernon Highlights UT Dallas Research Study Identifying Ifenprodil as a Possible COVID-19 Treatment

GlobeNewswire July 21, 2020

COVID-19: Algernon Announces First U.S. Clinical Trial Site in Florida

Featured Press Release July 16, 2020

Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenprodil for COVID-19

GlobeNewswire July 16, 2020

Algernon Screening Patients for Phase 2 Ifenprodil IPF & Chronic Cough Study in Australia

Stockhouse Editorial July 7, 2020

Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia

GlobeNewswire July 7, 2020

Algernon Pharmaceuticals Announces Extension of Exercise Date of Warrants

GlobeNewswire July 6, 2020

Algernon Receives Ethics Approval to Study Ifenprodil for COVID-19 in the US

Stockhouse Editorial June 25, 2020

Algernon Receives Ethics Approval for U.S. Sites for 2b/3 Human Study of Ifenprodil for COVID-19

GlobeNewswire June 25, 2020

The Top Healthcare Bullboards: April - June 2020

Stockhouse Editorial June 17, 2020

Algernon Pharmaceuticals Announces Deemed Exercise of Special Warrants

GlobeNewswire June 12, 2020

Company Advances Possible COVID-19 Treatment to Next Stage

Stockhouse Editorial June 12, 2020

IIROC Trade Resumption - AGN

Canada NewsWire June 4, 2020

Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19

GlobeNewswire June 4, 2020

IIROC Trading Halt - AGN

Canada NewsWire June 4, 2020

Investigational New Drug to Fight COVID-19 Submitted to FDA

Dave Jackson May 29, 2020

Algernon Pharmaceuticals Discusses Multinational Phase 2b/3 Ifenprodil COVID-19 Human Trial on BioPub Webcast Hosted by Dr. KSS MD PhD

GlobeNewswire May 28, 2020